Is Crinetics Pharmaceuticals Inc (CRNX) overvalued? · rev $35.9M
Crinetics Pharmaceuticals Inc (CRNX) is a biotechnology company listed on US.
This page asks whether Crinetics Pharmaceuticals Inc (CRNX) looks expensive on cached numbers — not a short thesis.
Latest reported CRNX revenue for 2026-06-30 was $35.9M. Net income was -$248.7M. CRNX currently screens at market cap $2.76B.
CRNX currently screens at market cap $2.76B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CRNX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CRNX stock page for the full model, not this heading.
Not investment advice.